• Medicine · May 2024

    Multicenter Study

    A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.

    • Saadettin Kilickap, Akin Ozturk, Nuri Karadurmus, Taner Korkmaz, Perran Fulden Yumuk, Irfan Cicin, Semra Paydas, Ebru Cilbir, Teoman Sakalar, Mukremin Uysal, Yesil CinkirHavvaHDepartment of Internal Diseases, Gaziantep University Faculty of Medicine, Division of Medical Oncology, Gaziantep, Turkey., Necdet Uskent, Necla Demir, Abdullah Sakin, Oldac Uras Dursun, Birkan Aver, TurhalNazim SerdarNSDepartment of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey., Serkan Keskin, Deniz Tural, Yesim Eralp, Bugdayci BasalFatmaFDepartment of Medical Oncology, Ankara Ataturk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey.Department of Medical Oncology, Lösante Children's and Adult Hospital, Ankara, Turkey., Hatime Arzu Yasar, SendurMehmet Ali NahitMANAnkara Atatürk Training and Research Hospital, Clinic of Medical Oncology, Ankara, Turkey.Department of Internal Medicine, Medical Oncology Division, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey., Umut Demirci, Erdem Cubukcu, Mustafa Karaagac, Burcu Cakar, TatliAli MuratAMDepartment of Internal Diseases, Division of Medical Oncology, Akdeniz University, Faculty of Medicine, Antalya, Turkey., Tarkan Yetisyigit, Semiha Urvay, Pinar Gursoy, Basak Oyan, Zeynep Hande Turna, Abdurrahman Isikdogan, Omer Fatih Olmez, Ozan Yazici, Devrim Cabuk, Mehmet Metin Seker, UnalOlcun UmitOUDepartment of Medical Oncology, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.Department of Medical Oncology-Chemotherapy, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Izmir, Turkey., Nezih Meydan, Sadi Kerem Okutur, Didem Tunali, Mustafa Erman, and Lung Sub-Group Study of the Turkish Oncology Group.
    • Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
    • Medicine (Baltimore). 2024 May 24; 103 (21): e37972e37972.

    AbstractTo evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…